Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002

British Journal of Haematology

Volumn 165, Issue 1, 2014, Pages 102-111

  Rizzieri, David A ^a   Johnson, Jeffrey L ^a   Byrd, John C ^b   Lozanski, Gerard ^b   Blum, Kristie A ^b   Powell, Bayard L ^c   Shea, Thomas C ^d   Nattam, Sreenivasa ^e   Hoke, Eva ^a   Cheson, Bruce D ^f   Larson, Richard A ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Fort Wayne Medical Oncology and Hematology   (United States)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

Burkitt leukaemia; Burkitt lymphoma; Chemo immunotherapy; Rituximab

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLEEDING; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGITIS; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC INDEX; ISCHEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN DISEASE; STOMATITIS; TREATMENT DURATION;

BURKITT LEUKAEMIA; BURKITT LYMPHOMA; CHEMO-IMMUNOTHERAPY; RITUXIMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896058462     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12736     Document Type: Article

References (34)

1. Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Gayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085-2093.
2. Barnes, J.A., Lacasce, A.S., Feng, Y., Toomey, C.E., Neuberg, D., Michaelson, J.S., Hochberg, E.P. & Abramson, J.S. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of Onocology, 22, 1859-1864.
3. Cheson, B.D., Pfistner, B., Juweid, M., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
4. Corazzelli, G., Frigeri, F., Russo, F., Frairia, C., Arcamone, M., Esposito, G., De Chiara, A., Morelli, E., Capobianco, G., Becchimanzi, C., Volzone, F., Saggese, M., Marcacci, G., De Filippi, R., Vitolo, U. & Pinto, A. (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. British Journal of Haematology, 156, 234-244.
5. Diebold, J., Jaffe, E.S., Raphael, M. & Warnke, R.A. (2001) World health organization classification of tumours. In: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (ed. by E.S. Jaffe, N.L. Harris, H. Stein & J.W. Vardiman ), pp. 181-184. IARC Press, Lyon.
6. Dunleavy, K., Pittaluga, S., Shovlin, M., Steinberg, S.M., Cole, D., Grant, C., Widemann, B., Staudt, L.M., Jaffe, E.S., Little, R.F. & Wilson, W.H. (2013) Low-intensity therapy in adults with Burkitt's lymphoma. New England Journal of Medicine, 369, 1915-1925.
7. Evens, A.M., Carson, K.R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P.M., Caimi, P.F., Sa, G. & Gordon, L.I. (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Annals of Oncology, 24, 3076-3081.
8. Ferreri, A.J., Bruno Ventre, M., Donadoni, G., Cattaneo, C., Fumagalli, L., Foppoli, M., Mappa, S., Govi, S., DiNocola, M., Rossi, G., Tirelli, U., Caligaris-Cappio, F., Spina, M. & Re, A. (2012) Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. British Journal of Haematology, 159, 252-255.
9. Hann, I.M., Eden, O.B., Barnes, J. & Pinkerton, C.R. (1990) MACHO chemotherapy for Stage IV B-cell lymphoma and B-cell acute lymphoblastic leukemia of childhood. British Journal of Haematology, 76, 359-364.
10. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
11. Herman, S.E., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., Johnson, A.J. & Byrd, J.C. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117, 6287-6296.
12. Hoelzer, D., Ludwig, W., Thiel, E., Gassmann, W., Löffler, H., Fonatsch, C., Rieder, H., Heil, G., Heinze, B., Arnold, R., Hossfeld, D., Büchner, T., Koch, P., Freund, M., Hiddemann, W., Maschmeyer, G., Heyll, A., Aul, C., Faak, T., Kuse, R., Ittel, T.H., Gramatzki, M., Diedrich, H., Kolbe, K., Fuhr, H.G., Fischer, K., Schadeck-Gressel, C., Weiss, A., Strohscheer, I., Metzner, B., Fabry, U., Gökbuget, N., Völkers, B., Messerer, D. & Uberla, K. (1996) Improved outcome in adult B cell acute lymphoblastic leukemia. Blood, 87, 495-508.
13. Hoelzer, D., Walewski, J., Döhner, H., Schmid, M., Hiddemann, W., Baumann, A., Serve, H., Dührsen, U., HÃ1ttman, A., Thiel, E., Dengler, J., Kneba, M., Schuler, M., Schmidt-Wolf, I., Beck, J., Hertenstein, B., Reichle, A., Domanska-Czys, K., Fietkau, R., Horst, H., Rieder, H., Schwartz, S., Burmeister, T. & Goekbuget, N. (2012) Substantially improved outcome of adult burkitt Non-Hodgkin lymphoma and leukemia patients with rituximab and a short-intensive Chemotherapy; Report of a Large Prospective Multicenter Trial. Blood ASH Annual Meeting abstracts, 120, 667a.
14. Intermesoli, T., Rambaldi, A., Rossi, G., Delaini, F., Romani, C., Pogliani, E.M., Pagani, C., Angelucci, E., Terruzzi, E., Levis, A., Cassibba, V., Mattei, D., Gianfaldoni, G., Scattolin, A.M., Di Bona, E., Oldani, E., Parolini, M., Gökbuget, N. & Bassan, R. (2013) High cure rates in Burkitt lymphoma and leukemia: a Northeren Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica, 98, 1718-1725.
15. Kalbfleisch, J. & Prentice, R. (1980) The Statistical Analysis of Failure Time Data. John Wiley & Sons Inc, New York.
16. Kasamon, Y.L., Brodsky, R.A., Borowitz, M.J., Ambinder, R.F., Crilley, P.A., Cho, S.Y., Tsai, H.L., Smith, B.D., Gladstone, D.E., Carraway, H.E., Huff, C.A., Matsui, W.H., Bolaños-Meade, J., Jones, R.J. & Swinnen, L.J. (2013) Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia and Lymphoma, 54, 483-490.
17. Larson, R.A., Dodge, R.K., Burns, C.P., Lee, E.J., Stone, R.M., Schulman, P., Duggan, D., Davey, F.R., Sobol, R.E. & Frankel, S.R. (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood, 85, 2025-2037.
18. Leoncini, L., Raphael, M., Stein, H., Harris, N.L., Jaffe, E.S. & Kluin, P.M. (2008) World health organization classification of tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (ed. by S. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman ), pp. 262-264. IARC Press, Lyon.
19. Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925-934.
20. Maruyama, D., Watanabe, T., Maeshima, A.M., Nomoto, J., Taniguchi, H., Azuma, T., Mori, M., Munakata, W., Kim, S.W., Kobayashi, Y., Matsuno, Y. & Tobinai, K. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediated between diffuse large B cell lymphoma and BL. International Journal of Hematology, 92, 732-743.
21. McMaster, M.L., Greer, J.P., Greco, F.A., Stein, R.S., Cousar, J.B., Flexner, J.M. & Hainsworth, J.D. (1991) Effective treatment of small non-cleaved cell lymphoma with high-intensity brief-duration chemotherapy. Journal of Clinical Oncology, 9, 941-946.
22. Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P. & Wright, D. (2002) An International evaluation of CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of the United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274.
23. Mead, G.M., Barrans, S.L., Qian, W., Walewski, J., Radford, J.A., Wolf, M., Clawson, S.M., Stenning, S.P., Yule, C.L. & Jack, A.S. (2008) A prospective clinicopathologic study of dose modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria. Blood, 112, 2248-2260.
24. Meinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schuab, G., Klein, C., Kabickova, E., Klapper, W., Attarbaschi, A., Schrappe, M. & Reiter, A. (2010) Phase 2 window study on rituximab in newly diagnosed pediatric mature B cell NHL lymphoma and Burkitt Leukemia. Journal of Clinical Oncology, 28, 3115-3121.
25. Mohamedbhai, S.G., Sibson, K., Marafioti, T., Kayani, I., Lowry, L., Goldstone, A.H., Linch, D.C. & Ardeshna, K.M. (2011) Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B cell Non-Hodgkin Lymphoma with proliferation index >95%. British Journal of Haematology, 152, 175-181.
26. Murphy, S.B., Bowman, W.P., Abromowitch, M., Mirro, J., Ochs, J., Rivera, G., Pui, C.H., Fariclough, D. & Berard, C.W. (1986) Results of treatment of advanced-stage Burkitt lymphoma and B-cell acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. Journal of Clinical Oncology, 4, 1732-1739.
27. Ponader, S., Chen, S.S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, M.J., O'Brien, S., Chiorazzi, N. & Burger, J.A. (2012) Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182-1189.
28. Rao, A., Valk, P.J.M., Metzeler, K.H., Acharya, C.R., Tuchman, S.A., Stevenson, M.M., Rizzieri, D.A., Delwel, R., Buske, C., Bohlander, S.K., Potti, A. & Löwenberg, B. (2009) Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. Journal of Clinical Oncology, 27, 5580-5586.
29. Rizzieri, D.A., Johnson, J., Niedzwiecki, D., Lee, E.J., Vardiman, J.W., Powell, B.L., Barcos, M., Bloomfield, C.D., Schiffer, C.A., Peterson, B.A., Canellos, G.P. & Larson, R.A. (2004) Intensive chemotherapy with and without cranial radiation for Burkitt Leukemia and Lymphoma final results of cancer and Leukemia Group B Study 9251. Cancer, 100, 1438-1448.
30. Schwenn, M.R., Blattner, S.R., Lynch, E. & Weinstein, H.J. (1991) HiCOM: a two-month intensive chemotherapy regimen for children with Stage III and IV Burkitt lymphoma and B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 9, 133-138.
31. Simon, R., Durrleman, S., Hoppe, R.T., Bonadonna, G., Bloomfield, C.D., Rudders, R.A., Cheson, B.D. & Berard, C.W. (1988) The non-Hodgkin's lymphoma Pathologic classification project: long-term follow up of 1, 153 patients with non-Hodgkin's lymphoma. Annals of Internal Medicine, 109, 939-945.
32. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
33. Thomas, D.A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.E., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-Like lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
34. Topp, M.S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Köhne-Volland, R., Brüggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P.A., Kneba, M., Einsese, H., Riethmüller, G., Hoelzer, D., Zugmaier, G. & Bargou, R.C. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29, 2493-2498.